H.C. Wainwright reiterates Buy rating on Emergent BioSolutions stock amid $56M contract

Emergent BioSolutions (EBS) received a reiterated Buy rating and $15.00 price target from H.C. Wainwright following a $56 million contract modification to supply ACAM2000 vaccine to the U.S. government, boosting projected total ACAM2000 sales to over $120 million this year. This, coupled with a $30 million anthrax vaccine contract, strengthens the company's revenue visibility despite mixed Q2 2025 results where EPS exceeded expectations but revenue missed. H.C. Wainwright's confidence is underpinned by the company's strong financial health, attractive P/E of 3.05, and a 44% stock gain over the past six months, with expectations for increasing demand for its biodefense products.

Analysis

H.C. Wainwright has reiterated its Buy rating and $15.00 price target for Emergent BioSolutions (EBS), primarily driven by a new $56 million contract modification for its ACAM2000 vaccine. This award boosts the projected total sales for the ACAM2000 product line to over $120 million for the year and reinforces the company's strategic relationship with the U.S. government's Administration for Strategic Preparedness and Response (ASPR). The positive contract momentum is further supported by a separate $30 million modification for its CYFENDUS anthrax vaccine. This news, however, is set against the backdrop of mixed Q2 2025 results, where the company significantly beat earnings expectations with an EPS of $0.16 against a projected loss of -$0.10, but missed on revenue, reporting $141 million versus an anticipated $174 million. Despite the revenue shortfall, the stock has demonstrated strong performance with a 44% gain over the past six months and trades at an attractive P/E ratio of 3.05, which supports the analyst's view that the stock is undervalued and that demand for its biodefense products is likely to increase over time.

Key Decisions for Investors

• Investors may find the stock attractive based on the strong contract flow, a reiterated 'Buy' rating with a $15.00 price target, and a low P/E ratio of 3.05, suggesting potential undervaluation despite recent momentum.
• It is crucial to monitor upcoming quarterly revenue reports closely, as the significant revenue miss in Q2 2025 signals a potential weakness in execution or broader demand that contrasts with the positive headline contract wins.
• Consider the company's heavy reliance on government biodefense contracts, which provides revenue visibility but also constitutes a concentration risk; long-term positions should be weighed against the stability and renewal prospects of these large-scale agreements.